Clinical Trials Logo

Clinical Trial Summary

In a recent study, Dronabinol was shown to reduce symptoms in patients with Functional Chest Pain (non-cardiac chest pain). Additionally, metabolic measures and patients' weights were not adversely affected by this regiment. In fact, some cholesterol measures trended in a favorable direction with Dronabinol. The study lasted 28 days and patients took Dronabinol twice daily. The goal of this current study focuses on reducing the dose of Dronabinol to see if the same goals can be achieved. More so, the study will be extended to 12 weeks to gain a more longitudinal picture of therapy with Dronabinol. It is hypothesized that reducing the dose and extending the duration will continue to show an improvement in symptoms as well as no adverse metabolic outcomes.


Clinical Trial Description

About 200,000 new cases of Functional Chest Pain (FCP) are diagnosed annually in USA. FCP is associated with poor quality of life and high health care expenditure. Gastroesophageal reflux disease (GERD), esophageal motility disorders, and psychological disorders may cause FCP. However, the mechanism(s) for FCP continue to be explored and include central and peripheral hypersensitivity as well as biomechanical dysfunction of the esophageal wall. CB1 receptor activation in synaptic clefts fine tunes neuronal firing and may in fact quell the over excitation associated with hypersensitivity.

Dronabinol, a cannabinoid receptor agonist with a preference for CB1 over CB2, is believed to reduce the esophageal hypersensitivity. CB1 receptors are located primarily on central and peripheral neurons (including the enteric nervous system) and myenteric plexus where they modulate neurotransmitter release. Activation of pre-junctional CB1 receptors may reduce excitatory enteric transmission and conceivably improve esophageal hyperreactivity and hypersensitivity, the hallmarks of FCP.

Previously, it was shown that Chest Pain Symptoms were greatly reduced when patients took 5 mg Dronabinol twice daily. Patients had very few side effects from this regiment although sedation was reported. The goal of this study focuses on reducing the dose of Dronabinol to 5 mg every other day, or essentially, one quarter of the dose. The effect of Dronabinol varies with CB1 receptor density in various tissues. It is hypothesized that at this reduced dose relief of chest pain will still be achieved without the sedating effects.

More so, Dronabinol at 5 mg twice daily failed to produce any adverse metabolic outcomes including measures of glucose, LDL, triglycerides, leptin, or transaminases. Dronabinol treatment tended to improve some of these measures although the study only lasted 28 days. Currently the hypothesis is that lower doses at a protracted time course will again fail to perturb homeostasis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02569073
Study type Interventional
Source Temple University
Contact
Status Withdrawn
Phase Phase 4
Start date June 21, 2017
Completion date September 1, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05054933 - Ultrasound Capsule Endoscopy for Esophagus Examination N/A
Completed NCT04090554 - Cytospongeâ„¢ Feasibility Study in Tanzania N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Recruiting NCT04481100 - CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer Phase 2
Completed NCT03859557 - The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
Completed NCT00977678 - Drop in Gastroscopy - Experience After 9 Months N/A
Recruiting NCT04068480 - Esophageal and Gastric Diseases With Robotically Controlled Magnetic Capsule Endoscopy
Completed NCT00874263 - Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies N/A
Terminated NCT00442507 - Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction Phase 2
Recruiting NCT03832959 - Esophageal Damage Protection During Pulmonary Vein Ablation. Pilot Study. N/A
Recruiting NCT05252078 - Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients Phase 2
Recruiting NCT00260585 - Esophageal Cancer Risk Registry
Completed NCT03187314 - Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer Phase 2
Recruiting NCT05004155 - Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
Recruiting NCT05469152 - Detachable String Magnetically Controlled Capsule Endoscopy for Follow-up of Patients With Esophageal Diseases N/A
Recruiting NCT05877300 - Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement Phase 1
Recruiting NCT03267355 - Indications and Outcomes of Endoscopic Ultrasound in Tanta N/A
Recruiting NCT00939263 - Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index N/A
Recruiting NCT05311787 - The Strategy of Implementation of the ERAS Protocol After Esophageal Surgery N/A